Beta 1 integrin expression: a marker of lymphatic metastases in cutaneous malignant melanoma.
BACKGROUND
Experimental evidence suggests that integrins are key regulators of the development of melanoma metastases, influencing both the likelihood and site of metastases. Whereas effective treatment of cutaneous melanoma remains surgical, elective lymph node dissection (ELND) is controversial. The present study was designed to investigate the relationship between integrin expression by a given primary melanoma and occult regional lymph node metastases.


METHODS
We studied beta 1 integrin expression, by quantitative immunohistochemistry using an image analyzer, in the primary melanomas of 90 ELND patients.


RESULTS
beta 1 integrin was expressed in > or = 10% of the primary tumor in 92% of cases eith lymph node involvement versus 9% of node negative cases (p < 0.001).


CONCLUSIONS
Our data demonstrate that quantitative immunohistochemistry for beta 1 integrin expression in primary melanomas can identify patients likely to have occult lymph node metastases. This suggests that beta 1 integrins play a role in the lymphatic dissemination of cutaneous melanoma.
Hieken
T J
TJ
Department of Surgical Oncology, University of Illinois at Chicago 60612-7322, USA.
Ronan
S G
SG
Farolan
M
M
Shilkaitis
A L
AL
Das Gupta
T K
TK
D014408:Biomarkers, Tumor / Q000032:analysis*; D005260:Female; D006801:Humans; D019012:Integrin beta1 / Q000032:analysis*; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000737:chemistry* / Q000556:secondary; D012878:Skin Neoplasms / Q000737:chemistry*
D014408:Biomarkers, Tumor; D019012:Integrin beta1